All of Nuvation Bio's previous posts, can be found here Nuvation Posts. The company is addressing the unmet need of ROS1 and glioma with two unique drugs.
From recent investor conferences that the company has participated, we were given some updated pipeline information. Two updates of interest include the following.
1. The 40 patient Grade 3 oligodendroglioma which is part of the SIGMA study NCT05303519, has objective response rate as the primary endpoint. The goal of achieving a 20% + response rate in this population, would be seen as positive over standard of care chemotherapy for these patients. The study will be conducted as an Open-Label single arm.
2. Yet To Be Announced: Safusidenib treatment for those patients that have been on approved drug vorasidenib, and over time have failed. The endpoint again would be objective response rate, with a goal of achieving 20%.
Both trials could benefit from ORR as a quicker endpoint read-out, a smaller number of patients, with potential 2027 data. The daily chart of Nuvation below displays a consolidation range over the past two and a half months. The high of $5.29 and low support at $4.05. This consolidation chart pattern has the potential to breakout strong.
